Leap Therapeutics, Inc. - LPTX STOCK NEWS

Leica Biosystems has partnered with Leap Therapeutics (NASDAQ: LPTX) to create a companion diagnostic for detecting Dickkopf-related protein 1 (DKK1), a protein associated with poor cancer outcomes. This diagnostic will support the clinical development of Leap's DKN-01 therapy, a humanized monoclonal antibody currently in Phase 2 trials for gastric cancer. The test employs RNAscope™ technology to identify patients likely to benefit from DKN-01. This collaboration aims to enhance personalized cancer treatment based on biomarker profiles.

Leap Therapeutics (Nasdaq: LPTX), a biotechnology firm specializing in targeted and immuno-oncology therapies, will present a corporate overview at the B. Riley Securities Oncology Investor Conference on January 27, 2022, at 10:00 a.m. Eastern Time. The event will be virtual and accessible via the company’s website, where a replay will also be available. Leap's leading candidate, DKN-01, targets the Dickkopf-1 protein and is currently in clinical trials for various cancers. A partnership with BeiGene has been established for developing DKN-01 in Asia, Australia, and New Zealand.

Leap Therapeutics (Nasdaq: LPTX) announced that updated data from the DisTinGuish Phase 2a trial will be presented at the ASCO Gastrointestinal Cancers Symposium from January 20-22, 2022. The trial evaluates DKN-01, an anti-DKK1 antibody, combined with BeiGene's tislelizumab in patients with gastric and gastroesophageal junction cancer. Notable findings show promising efficacy in DKK1-high patients and improved safety tolerability. A conference call is scheduled for January 21, 2022, to discuss the results. The study is ongoing, focusing on both first-line and second-line therapies.

Leap Therapeutics (Nasdaq: LPTX) announced that its President and CEO, Douglas E. Onsi, will present a corporate overview at the H.C. Wainwright BioConnect 2022 Conference from January 10-13, 2022. The presentation will be available on January 10 at 7:00 a.m. Eastern Time via their Investors page.

The company focuses on developing targeted and immuno-oncology therapeutics, with DKN-01 as their lead candidate currently in trials for various cancers.

Leap Therapeutics (Nasdaq: LPTX) will present a corporate overview at the 40th Annual J.P. Morgan Healthcare Conference on January 13, 2022, at 9:00 a.m. Eastern Time. Douglas E. Onsi, President and CEO, will lead the presentation, which will be accessible via a live webcast on the company's Investors page. Leap Therapeutics focuses on developing targeted therapies, including DKN-01, a monoclonal antibody in clinical trials for various cancers. For more information, visit www.leaptx.com.

Leap Therapeutics, Inc. (Nasdaq: LPTX) announced participation in the Piper Sandler 33rd Annual Virtual Healthcare Conference from November 29 to December 2, 2021. Members of the senior management team will engage in a fireside chat, with a replay available on the company’s Investors page starting November 22, 2021, at 10:00 a.m. ET. Leap is focused on developing targeted immuno-oncology therapeutics, with its lead candidate, DKN-01, currently in trials for various cancers. For more details, visit Leap's website.

Leap Therapeutics (Nasdaq:LPTX) reported its third quarter financial results for 2021, revealing a net loss of $11.1 million, up from $7.1 million in Q3 2020. The company successfully completed a $103.6 million public offering, netting $96.8 million. Positive initial data from the DisTinGuish Study of DKN-01 plus tislelizumab indicated a 68.2% overall response rate in first-line gastric cancer patients. R&D expenses rose to $10.1 million, attributed to increased clinical trial costs and staffing. Cash and equivalents stood at $124.8 million as of September 30, 2021.

Leap Therapeutics, Inc. (Nasdaq:LPTX) closed a public offering of 27,568,072 shares of common stock, raising approximately $104 million. This amount includes $7.25 million from collaborator BeiGene, Ltd. The offering included the additional sale of 4,740,000 shares due to underwriters' exercised options and 8,771,928 pre-funded warrants. Piper Sandler, Raymond James, and Mizuho acted as book-running managers. Proceeds will assist in advancing Leap's clinical programs, particularly for their leading candidate, DKN-01, which targets various cancers.

Leap Therapeutics (Nasdaq:LPTX) announced a public offering of common stock priced at $2.85 per share, alongside pre-funded warrants at $2.849 each. This offering is projected to raise approximately $90 million in gross proceeds, anticipated to close around September 24, 2021. The company will use the funds for further development of its drug candidate DKN-01, manufacturing clinical trial materials, and general corporate purposes. The offering includes an option for underwriters to purchase an additional 4,740,000 shares.